PDF (15.90 MB) - Boehringer Ingelheim Annual Report 2012

More documents

Recommendations

Info

PERSPECTIVES FOR THE SOCIETYOF TOMORROWIn the Research Institute of Molecular Pathology (IMP) in Vienna, Austria,and the Institute of Molecular Biology (IMB) in Mainz, Germany, BoehringerIngelheim and the Boehringer Ingelheim Foundation are supporting twobasic research institutes. One of the questions which drives us is what canwe do today in order to be able to offer innovative solutions to the then mostpressing diseases in 15 to 20 years time.COOPERATION BETWEEN ACADEMICAND INDUSTRIAL RESEARCH[ in conversation with ] [ and ]Andreas Barner,Chairman of the Board ofManaging Directors,Boehringer IngelheimDr Jan-Michael Peters,Acting Director Science,Institute of Molecular Pathology,Vienna, AustriaProf. Christof Niehrs,Founding Director,Institute for Molecular Biology,Mainz, Germany30 Boehringer Ingelheim annual report 2012
corporate responsibilityperspectives for societyFor more information aboutIMB and IMP:see following pagesandreas barner: Through ourcooperation with basic research wewant to create new opportunities fordiagnoses and therapies. For this it isnecessary to have broad access to newlyemerging therapeutic concepts andnew technology platforms. These alliancesenable Boehringer Ingelheim,in cooperation with the scientific community,to integrate outside innovationsinto the company in a reliableand trusting partnership.Invention and innovation – What doesbasic research mean?jan-michael peters: Inventionand innovation and, I would add, discovery,are the core of science. Thatapplies for technological developmentthat often determines how much we investigate,and are thereby able to understand,as too for the field of biology.The freedom of basic research is requiredfor discoveries, which ultimatelydepend on the idea or intuitionof individuals. Planning and predictingcannot deliver them. New stimulifor developing medicines or othermedical progress also come from independentbasic research. That is oneof the many sound reasons to promotethem on a broad front, even when theirusability is not always immediatelyevident.And what does discovery and innovationmean for our research-driven pharmaceuticalcompany?andreas barner: Our researchersrealise innovations in human and veterinarypharmaceuticals in our ownnetwork of research and developmentsites. Here substances are developedinto medications. Examples are the medications,such as pradaxa®, spiriva®or trajenta®. We are guided by theidea of researching therapies for diseaseswith great medical need. Researchand development is an integralelement of our family-owned companyBoehringer Ingelheim.What advantages come fromcooperations between the twoworlds of research?christof niehrs: The pharmaceuticalindustry also needs welleducatedscientists and they come fromhigh-performance universities. Theseare, however, frequently underfinanced.Industry’s commitment can play animportant role in order to make a basicresearch location perform better andbe more attractive.jan-michael peters: Very muchso! Where industry and academic researchcooperate, ideas and discoveriesare tested early on for their possibleapplications, sometimes even beforeacademic researchers are aware of them.Conversely, basic research can in manydifferent ways benefit from, for example,the development of active ingredientsthat open up new experimentalopportunities.What will successful research look likein the future?christof niehrs: Research willincreasingly be conducted in largenetworks. The trend is clearly towardslarge-scale projects, as in physics. Allmanner of consortia, as in genomics,are an example of this. This trend willcontinue and grow stronger. Furthermore,methods will be increasinglyspecific and complex. In the past, alaboratory was able to cover only somefields, such a biochemistry, developmentalbiology or physiology.Today, scientific work bridges an everlargerspan from the biochemistry ofphosphorylated proteins to knock-outmice, from signal transduction analysisto their bioinformatic simulationand analysis.andreas barner: Successfulresearch takes place when we absorbnew ideas and develop therapeuticoptions beyond current scientific,metho dical and institutional boundaries.Perspectives for the society of tomorrow31
Page 1 and 2: Value through InnovationCorporate M
Page 3 and 4: our businesses66 [ prescription med
Page 5 and 6: value through innovationextracts fr
Page 7 and 8: value through innovationperspective
Page 9 and 10: perspectives for boehringer ingelhe
Page 11 and 12: corporate responsibilityperspective
Page 13 and 14: perspectives for societynadezhda ch
Page 31: corporate responsibilityperspective
Page 41 and 42: esearch & developmentperspectives f
Page 43 and 44: eckhard burbachretiree (formerly he
Page 46 and 47: RESEARCH PARTNERSHIPS WITHACADEMIA
Page 48 and 49: collaborate innovate accelerateTRAN
Page 50 and 51: GLORIA-AF®Registry programme for p
Page 52 and 53: BOEHRINGER INGELHEIM ONCOLOGY FRANC
Page 54 and 55: AFATINIB BLOCKS THE ERBB RECEPTORSE
Page 56 and 57: HEPTATIS C VIRUS (HCV) INFECTIONHCV
Page 58 and 59: 1viral entryrnareleasernatranslated
Page 60 and 61: 12THE MAIN COMPLICATIONS OF DIABETE
Page 62 and 63: ASTHMAAsthma is a chronic disease c
Page 64 and 65: THERAPEUTIC AREA (TA) REVIEW CORE T
Page 66 and 67: 6° 59' 15" N, 125° 16' 15" Eapo,
Page 68 and 69: icardo f. solitariadistrict manager
Page 70 and 71: PERSPECTIVES FORBETTER HEALTHBoehri
Page 72 and 73: “My photo shows Frau Röhrigfrom
Page 74 and 75: OUR CARDIOVASCULAR PORTFOLIOaggreno
Page 76 and 77: HOW ATRIAL FIBRILLATION (AF)LEADS T
Page 78 and 79: FINDING THE RIGHT MOLECULE“Findin
Page 80 and 81: PATIENTS AT CARDIOVASCULAR RISKMost
Page 82 and 83:
TRAJENTA® / TRADJENTA®trajenta®
Page 84 and 85:
WORLD DIABETES DAYWorld Diabetes Da
Page 86 and 87:
SPIRIVA®: 10 YEARS AND MORE OF CLI
Page 88 and 89:
BEHAVIOUR CHANGE INTYPE 2 DIABETEST
Page 90 and 91:
Rapid progress in global healthcare
Page 92 and 93:
KEY GOALS OF GLOBAL BUSINESS SERVIC
Page 94 and 95:
“The perspectives that open upune
Page 96 and 97:
OUR GLOBAL SWITCH TEAMThe Switch un
Page 98 and 99:
“For me, the photo shows thatthe
Page 100 and 101:
2 Disposable single use bioreactorw
Page 102 and 103:
“The hard-working beessuccessfull
Page 104 and 105:
“There are many things and experi
Page 106 and 107:
OUR GLOBAL SCIENTIFIC NET WORKIN AN
Page 108 and 109:
2 31 Scientists in Hannover working
Page 110 and 111:
“Living and working on a differen
Page 112 and 113:
1 Phoenix, the first captive-bredOr
Page 114 and 115:
55° 21' 0" N, 131° 40' 24" Wketch
Page 116 and 117:
scott zhangstrategic effectiveness
Page 118 and 119:
PERSPECTIVES FORQUALITY IN OPERATIO
Page 120 and 121:
With the quality risk management sy
Page 122 and 123:
In order to ensure patient safety,
Page 124 and 125:
37° 34' 48" N, 14° 16' 34" Esicil
Page 126 and 127:
37° 34' 48" N, 14° 16' 34" Esicil
Page 128 and 129:
PERSPECTIVES FORESTABLISHED MARKETS
Page 130 and 131:
Spain is one of the countries struc
Page 132 and 133:
21 View of Athens.2 Production site
Page 134 and 135:
1 View of San Francisco, the leadin
Page 136 and 137:
211 View of Tokyo with Japan’s hi
Page 138 and 139:
IF YOU HAVE ANY QUERIES OR COMMENTS
Page 140 and 141:
Value through InnovationBusiness Ye
Page 142 and 143:
product portfolio70 [ branded presc
Page 144 and 145:
usiness year 2012our companyOUR COM
Page 146 and 147:
usiness year 2012the shareholders
Page 148 and 149:
usiness year 2012the shareholders
Page 150 and 151:
usiness year 2012 key aspects 2012S
Page 152 and 153:
usiness year 2012 key aspects 2012F
Page 154 and 155:
usiness year 2012 key aspects 2012B
Page 156 and 157:
usiness year 2012corporate bodiesCO
Page 158 and 159:
usiness year 2012group management r
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
usiness year 2012consolidated finan
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
usiness year 2012auditor’s report
Page 208 and 209:
product portfolioa selection2012PRO
Page 210 and 211:
product portfoliobranded prescripti
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
product portfolioconsumer health ca
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
product portfolioanimal healthIndic
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
usiness year 2012financial data2006
Page 238:
www.boehringer-ingelheim.comannualr
show all

PDF (15.90 MB) - Boehringer Ingelheim Annual Report 2012

Create successful ePaper yourself

Delete template?

Save as template?